CDNA
CareDx, Inc
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$50.88
+2.05%Jul 31, 2026, 22:45 UTC
CareDx granted 15,822 restricted stock units to newly appointed Executive Advisor James McNally as an inducement material to his employment on July 30, 2026.
Source:Jul 30, 2026, 22:06 UTC
CareDx reported its second-quarter 2026 financial results, with revenue growing 52% year-over-year.
Source:Jul 30, 2026, 22:06 UTC
CareDx began integrating the recently acquired NavDx specialty oncology platform.
Source:Jul 16, 2026, 12:30 UTC
CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process for molecular testing in solid organ transplant, affirming coverage for its transplant surveillance offerings in kidney, heart, and lung.
Source:Jul 1, 2026, 20:05 UTC
CareDx completed its acquisition of Naveris, extending into specialty oncology.
Source:Jul 1, 2026, 06:00 UTC
Eurobio Scientific has finalized the acquisition of CareDX's transplant Lab Product division.